Nanomedicine is the use of materials engineered at the nanometer scale, typically between 1 and 100 nanometers, to diagnose, treat, or prevent disease. To put that size in perspective, a single nanometer is roughly one hundred-thousandth the width of a human hair. At this scale, particles behave differently than bulk materials: they can slip through biological barriers, carry drug payloads directly into tumors, and protect fragile molecules like mRNA from breaking down in the bloodstream. The COVID-19 mRNA vaccines and a growing list of cancer therapies are among the most visible real-world examples, but the field stretches into diagnostics, gene editing, and brain-targeted delivery.
Why Size Matters for Drug Delivery
Most conventional drugs flood the entire body. You swallow a pill or receive an injection, and the active ingredient circulates everywhere, affecting healthy tissue along with the diseased target. Nanomedicine changes this equation by packaging drugs inside or onto tiny carriers that can be steered, filtered, or passively concentrated in specific tissues. These carriers come in many forms: liposomes (tiny fat-based bubbles), polymer nanoparticles, dendrimers (branching molecular trees), carbon nanotubes, metallic particles, and more.1PubMed Central. Nanoparticles in Drug Delivery: From History to Therapeutic Applications Each type has strengths suited to different tasks. Liposomes, for instance, are especially good at encapsulating water-soluble drugs, while gold nanoparticles can absorb light and convert it to heat.
The first nanomedicine to gain FDA approval was Doxil in 1995, a formulation of the chemotherapy drug doxorubicin enclosed in tiny liposomes coated with a polymer called PEG. That coating helped the liposomes dodge the immune system long enough to accumulate in tumors, reducing the severe heart damage that free doxorubicin often caused.2PubMed. Doxil®–the first FDA-approved nano-drug: lessons learned Doxil set key pharmacological principles for the field: prolonged circulation, slow drug release, and preferential tumor accumulation.3BMJ Oncology. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective Nearly thirty years later, those same principles still underpin many of the nanoparticle-based therapies in development and on the market.
How Nanoparticles Reach Tumors
Solid tumors grow fast, and the blood vessels they recruit to feed that growth are often sloppy and leaky compared with normal vasculature. At the same time, tumors tend to have poor lymphatic drainage, so anything that leaks in has trouble getting back out. Nanoparticles exploit both of these quirks through what researchers call the enhanced permeability and retention effect, or EPR effect. Drug-loaded nanoparticles slip through the gaps in leaky tumor vessels and then get trapped in the tumor bed because there is no efficient drainage to flush them away.4PubMed Central. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? This passive targeting means a higher fraction of the drug ends up in the tumor rather than bathing healthy organs.
The EPR effect is real, but it has limits. It varies enormously between tumor types and even between patients. Some tumors have vessels that are only mildly permeable; others are heavily fibrotic, preventing nanoparticles from penetrating deep into the tissue. Researchers have explored strategies like combining nanomedicines with agents that remodel tumor blood vessels or loosen the dense extracellular matrix, all in an effort to make the EPR effect more reliable.5PubMed Central. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment This inconsistency is one reason nanomedicine hasn’t yet replaced conventional chemotherapy outright: a delivery strategy that works beautifully in one patient’s tumor may underperform in another’s.
Active Targeting and Smart Release
To go beyond passive accumulation, researchers attach targeting molecules to the surface of nanoparticles. These molecules, called ligands, recognize and bind to specific receptors that cancer cells display in abundance. Folate, transferrin, antibodies, peptides, and aptamers are among the most commonly tested options.6PubMed Central. Receptor-targeted nanocarriers for therapeutic delivery to cancer Once a ligand locks onto a receptor on the cancer cell surface, the cell pulls the entire nanoparticle inside, delivering the drug payload directly into the cell’s interior. Studies have shown that this active targeting approach can improve therapeutic responses compared with untargeted nanoparticles, both in cell cultures and in animal models.7PubMed Central. Nanoparticle ligand presentation for targeting solid tumors
A related strategy takes advantage of the unusual environment inside tumors. Tumor tissue tends to be more acidic than healthy tissue, contains elevated levels of certain enzymes, and often lacks adequate oxygen. Researchers have designed “smart” nanoplatforms that remain stable during circulation but release their drug cargo when they encounter these tumor-specific conditions. For instance, a pH-sensitive nanoparticle might hold its drug tightly at the neutral pH of blood but open up in the acidic environment of a tumor.8PubMed Central. Smart Nanoplatforms Responding to the Tumor Microenvironment for Precise Drug Delivery in Cancer Therapy Combining active targeting with environment-responsive release is a major focus of current clinical research, though most of these systems are still working through trials rather than sitting on pharmacy shelves.
Lipid Nanoparticles and mRNA Vaccines
The technology that introduced most people to nanomedicine was the COVID-19 mRNA vaccine. Messenger RNA is a fragile molecule. Left unprotected, enzymes in your blood and tissues would shred it within minutes. Lipid nanoparticles (LNPs) solve this problem by wrapping the mRNA inside a shell of specially chosen fats. The resulting structure protects the mRNA from degradation and helps it reach the inside of your cells, where it can instruct the cell’s machinery to build the target protein, in this case the SARS-CoV-2 spike protein.9Nature Reviews Materials. Lipid nanoparticles for mRNA delivery
Getting mRNA out of the nanoparticle and into the cell’s working space is itself a tricky step. After a cell swallows an LNP, the particle ends up trapped inside a small compartment called an endosome. If it stays there, the mRNA never reaches the cellular machinery that could read it. The LNP’s ionizable lipids change their charge in the acidic endosomal environment, which helps the particle fuse with the endosomal membrane and release its mRNA cargo into the cell’s interior.10Nature Communications. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells Recent work suggests this escape happens through a mechanism where the endosomal membrane buds and collapses, and that the released mRNA initially forms an aggregate with lipids that must dissolve before translation can begin.11PubMed Central. Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data This dissolution step may be a bottleneck that limits how much of the delivered mRNA actually gets used.
An unexpected finding from vaccine research is that the lipid nanoparticles themselves appear to act as immune boosters. In mouse studies using both influenza and SARS-CoV-2 vaccines, LNPs promoted strong responses from immune cells involved in building lasting immunity, including the long-lived plasma cells and memory B cells that keep you protected months or years after vaccination.12PubMed Central. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses Ionizable lipids in the LNP formulation appear to trigger innate immune pathways, which means the delivery vehicle isn’t just a passive wrapper; it actively shapes how well the vaccine works.13PubMed. Lipid Nanoparticle: Beyond Delivery Vehicle-Unveiling Its Immunological Adjuvant Potential This dual role is both a benefit and something that needs careful calibration, because too much immune stimulation from the lipids could contribute to the reactogenicity (the sore arm, fever, and fatigue) that some people experience.
Gold Nanoparticles and Photothermal Therapy
Not all nanomedicine involves delivering a drug payload. Gold nanoparticles can absorb light at specific wavelengths and convert it directly into heat, a property known as localized plasmon surface resonance. When these particles accumulate in a tumor and are then hit with a near-infrared laser, the resulting heat can destroy cancer cells directly. Adjusting the shape and size of gold nanoparticles shifts the wavelength of light they absorb most efficiently, which lets researchers tune them to work with near-infrared light that penetrates deeper into tissue.14PubMed Central. Gold Nanoparticles for Photothermal Cancer Therapy
This photothermal approach has been combined with photodynamic therapy, in which nanoparticles generate reactive oxygen species that chemically damage cancer cells. Composite nanoparticles incorporating gold have demonstrated high photothermal conversion efficiency and strong generation of cell-damaging radicals under near-infrared laser exposure in laboratory experiments.15PubMed Central. Near-Infrared Driven Gold Nanoparticles-Decorated g-C(3)N(4)/SnS(2) Heterostructure through Photodynamic and Photothermal Therapy for Cancer Treatment Because these same particles also produce signals detectable by imaging equipment, they can serve a dual purpose: diagnose where the tumor is and then treat it during the same procedure. Researchers call this combined capability “theranostics.” Magnetic nanoparticles, especially iron oxide particles, fill a similar diagnostic niche as contrast agents for MRI scans, and ongoing work is exploring how to pair that imaging capability with therapeutic payloads.16PubMed Central. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy
What Happens to Nanoparticles Inside the Body
One of the trickiest aspects of nanomedicine is controlling what happens to particles after injection. Within seconds of entering the bloodstream, nanoparticles become coated with a layer of blood proteins, forming what’s called a “protein corona.” This corona effectively disguises whatever surface the engineers originally designed, and it can dramatically alter how long the particles circulate, where they end up, and whether immune cells gobble them up.17PubMed Central. Glycopolymeric Nanoparticles Enrich Less Immunogenic Protein Coronas, Reduce Mononuclear Phagocyte Clearance, and Improve Tumor Delivery Compared to PEGylated Nanoparticles
Even “biomimetic” nanoparticles wrapped in real cell membranes, a strategy meant to trick the immune system into thinking the particle is a normal cell, aren’t immune to this problem. Research has shown that adsorbed proteins can mask the very surface markers meant to protect the particle. In one study, about 88% of CD47 markers on red-blood-cell-membrane-coated nanoparticles were hidden by the protein corona after exposure to serum, shifting how the liver processed the particles and redirecting uptake from immune cells to ordinary liver cells.18PubMed. Protein Corona Reprograms Hepatic Clearance Pathways of Biomimetic Nanoparticles via Ligand Masking and Differential Protein Enrichment Understanding and controlling the protein corona is now considered essential for designing nanoparticles that actually perform as intended in a living body.19PubMed Central. Influence of the protein corona on hematopoietic stem and progenitor cell uptake and macrophage clearance of membrane-wrapped nanoparticles
The most common strategy for extending nanoparticle circulation time has been coating them with PEG, the same polymer used on Doxil back in 1995. PEG creates a hydrophilic shield that reduces protein adsorption, aggregation, and immune cell recognition, keeping particles in the blood longer.20PubMed Central. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery But PEG has its own complications. Somewhere between 20% and 70% of people already carry antibodies against PEG, likely from widespread exposure through cosmetics, laxatives, and other consumer products.21PubMed. The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes These pre-existing antibodies can reduce the effectiveness of PEGylated nanomedicines. Even without prior antibodies, repeated doses of PEGylated nanoparticles can trigger the body to produce anti-PEG antibodies after the first injection, leading to faster clearance on subsequent doses, a phenomenon called accelerated blood clearance. In rats given clinically relevant doses of PEGylated lipid nanoparticles, researchers observed significantly reduced circulation of the particles after a second injection compared with the first.22npj Vaccines. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats This is an active area of concern for any therapy requiring repeated dosing, and it helps explain the interest in alternative surface coatings like glycopolymers that may attract a less immunogenic protein corona.
Getting Past the Blood-Brain Barrier
The blood-brain barrier is one of the body’s most formidable defenses, a tightly sealed wall of cells lining the brain’s blood vessels that blocks the vast majority of drugs from reaching brain tissue. This is a serious clinical problem because it means many promising drugs for brain cancers and neurological diseases never make it to their target. Nanoparticles offer a potential workaround. Their small size and the ability to engineer their surfaces with specific ligands allow researchers to exploit the brain’s own transport systems, including receptor-mediated transcytosis, where a nanoparticle hitches a ride on receptors that the barrier’s cells use to shuttle select molecules from blood to brain.23PubMed Central. Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology
The particle’s physical characteristics matter enormously for blood-brain barrier crossing. Size, shape, surface charge, and what ligands are attached all influence whether a nanoparticle can make the trip.24ACS Nano. Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier Most of this work is preclinical, meaning it has been demonstrated in animal models or cell cultures but hasn’t yet produced approved human therapies for brain tumors. Still, the ability to ferry chemotherapy or immunotherapy agents across a barrier that currently stops them cold would be a genuine breakthrough, and it’s one of the most actively pursued frontiers in the field.
Scaling Up Production
A frequent gap between promising lab results and actual patient access is manufacturing. Making a batch of precisely defined nanoparticles for a few dozen mice is very different from producing billions of vaccine doses. The mRNA COVID-19 vaccines forced the field to solve this problem at unprecedented speed. The core technology that made it possible was microfluidic mixing, where lipid and mRNA solutions are pushed through tiny channels at controlled speeds to form uniform nanoparticles. But individual microfluidic channels produce only small volumes.
To meet global demand, researchers developed parallelized microfluidic devices that run many channels simultaneously. One design incorporates up to 256 nanoparticle-generating units on a single chip, achieving production rates of up to 17 liters per hour while maintaining the same particle quality and potency seen at bench scale.25PubMed Central. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines Another team demonstrated a 128-channel parallelized device that achieved more than a hundredfold increase in production rate without sacrificing the physical properties or effectiveness of the resulting nanoparticles.26Nano Letters. Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device The existence of this scalable manufacturing infrastructure means that the next generation of LNP-based therapies, whether vaccines for other diseases or cancer treatments, won’t face the same production bottleneck that defined early 2021.
Regulatory Hurdles
Nanomedicines don’t fit neatly into traditional drug categories. A nanoparticle loaded with a chemotherapy drug is both a device (the carrier) and a pharmaceutical (the drug), and sometimes a biological product (if it contains mRNA or antibodies). Both the FDA and the European Medicines Agency have developed frameworks for evaluating these products, but the regulatory path remains more complex and less standardized than for a conventional small-molecule pill.27PubMed Central. Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks
Among the biggest challenges are characterizing the product thoroughly enough to satisfy regulators. Because nanoparticle behavior depends on subtle physical and chemical details, like size distribution, surface charge, how quickly the drug leaks out, and how the particle interacts with blood, the quality testing required is more extensive than for a simple dissolved drug. Scaling from lab batch to commercial production introduces its own risks: a slight change in mixing speed or temperature can shift particle size in ways that alter how the drug distributes in the body. Regulatory bodies have increasingly recommended a “quality by design” approach, where manufacturers identify and control the critical variables from the earliest stages of development rather than trying to characterize the final product after the fact.28PubMed. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development
Delivering Drugs Through Mucosal Barriers
Not every nanomedicine enters the body by injection. There is growing interest in delivering nanoparticles through the lungs, nose, and gut, routes that could make treatments more convenient and open up new targets. But these routes come with their own obstacles, chief among them mucus. The sticky gel lining your airways and digestive tract is designed to trap and clear foreign particles, which means an inhaled nanoparticle faces a race: it has to get through the mucus layer and reach the underlying cells before being swept away.
Two main strategies have emerged. Mucoadhesive nanoparticles are designed to stick to the mucus layer and release their drug slowly over time. Mucopenetrating nanoparticles take the opposite approach: they’re engineered with slippery surfaces (often using dense PEG coatings) that let them slip through the mucus mesh and reach the epithelial cells beneath.29PubMed. Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier Both approaches have shown proof of concept in laboratory mucus models, but translating them into approved inhaled or oral nanomedicines is still in its early stages.30PubMed Central. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung If successful, inhaled nanomedicines could deliver higher drug concentrations directly to diseased lung tissue while reducing the systemic side effects that come with intravenous administration.
Nanoparticles for Gene Editing
CRISPR gene-editing tools are powerful, but getting them into the right cells inside a living body is a significant challenge. Viral vectors are the traditional delivery vehicle, yet they carry risks including immune reactions and the potential for the viral DNA to insert in unwanted locations. Lipid nanoparticles offer a non-viral alternative. Researchers have engineered modified LNPs that can deliver CRISPR components directly into specific tissues after an intravenous injection. In mouse studies, a single injection facilitated gene editing in muscle, brain, liver, and lungs, and multiplexed editing of six genes simultaneously in lung tissue has been demonstrated.31Nature Communications. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
This approach is still preclinical, but it points toward a future where genetic diseases could be treated with a straightforward infusion rather than complex viral gene therapy. The same LNP engineering principles developed for mRNA vaccines, including the ionizable lipids that enable endosomal escape, are being adapted and optimized for CRISPR delivery. The overlap between vaccine technology and gene-editing delivery is one of the clearest examples of how the COVID-19 era accelerated not just one product but an entire platform of therapeutics.